Lina H. H. Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lina H. H. Le has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hannah Huckstep
Murdoch Children’s Research Institute, The Royal Children’s Hospital, Melbourne, VIC 3052, Australia
2 shared publications - Richard J. Mills
Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Australia
2 shared publications - Sean J. Humphrey
Murdoch Children’s Research Institute, The Royal Children’s Hospital, Melbourne, VIC 3052, Australia
2 shared publications - Andrew Philp
Centre for Healthy Ageing, Centenary Institute, Sydney, NSW, Australia
1 shared publication Andrew Stuart Palmer
School of Sport, Exercise and Rehabilitation, University of Technology Sydney, Sydney, NSW, Australia
1 shared publicationBrendan Griffen
Dynomics Inc, San Francisco, USA
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (9) , 795-806
Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy
Truncating variants in the ALPK3 gene (encoding alpha protein kinase 3) cause severe cardiomyopathy for which no curative treatment exists 1–3 . Here we establish an adeno-associated virus (AAV)-mediated gene replacement therapy to deliver full-length human ALPK3 . AAV- ALPK3 prevented disease in neonatal Alpk3- mutant mice and reversed established pathology in adults, with proteomic analysis demonstrating reversal of more than 95% of the molecular disease signature. Beyond ALPK3 deficiency, we explored broader therapeutic potential based on ALPK3’s regulatory role in proteostasis, a pathway commonly disrupted across cardiomyopathies. ALPK3 expression is reduced in cardiomyocytes with TTN -truncating variants, the most prevalent cause of dilated cardiomyopathy, and the encoded titin protein has a protein quality control network in common with ALPK3. AAV- ALPK3 restored contractile function in human cardiac organoids with an ALPK3 - or TTN -truncating variant. These findings provide proof of concept for ALPK3 gene therapy in patients with ALPK3 cardiomyopathy and reveal potential for indication expansion to cardiomyopathies associated with TTN -truncating variants, which are not amenable to gene replacement therapy due to size limitations.
- 19 August 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (9) , 795-806
Open AccessAlpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy
Truncating variants in the ALPK3 gene (encoding alpha protein kinase 3) cause severe cardiomyopathy for which no curative treatment exists 1–3 . Here we establish an adeno-associated virus (AAV)-mediated gene replacement therapy to deliver full-length human ALPK3 . AAV- ALPK3 prevented disease in neonatal Alpk3- mutant mice and reversed established pathology in adults, with proteomic analysis demonstrating reversal of more than 95% of the molecular disease signature. Beyond ALPK3 deficiency, we explored broader therapeutic potential based on ALPK3’s regulatory role in proteostasis, a pathway commonly disrupted across cardiomyopathies. ALPK3 expression is reduced in cardiomyocytes with TTN -truncating variants, the most prevalent cause of dilated cardiomyopathy, and the encoded titin protein has a protein quality control network in common with ALPK3. AAV- ALPK3 restored contractile function in human cardiac organoids with an ALPK3 - or TTN -truncating variant. These findings provide proof of concept for ALPK3 gene therapy in patients with ALPK3 cardiomyopathy and reveal potential for indication expansion to cardiomyopathies associated with TTN -truncating variants, which are not amenable to gene replacement therapy due to size limitations.
- Open Access
- 25 June 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (3)
Marginal Zone Lymphoma is associated with dysregulated T cell immunity which is not altered by ibrutinib-venetoclax treatment
- 25 June 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (3)
Open AccessMarginal Zone Lymphoma is associated with dysregulated T cell immunity which is not altered by ibrutinib-venetoclax treatment
- Open Access
Ageing blunts the phospho-proteomic response to resistance exercise in humans
Ageing blunts the adaptive growth response in human skeletal muscle. To define the molecular processes underlying this impairment, we performed unbiased analysis of the phosphoproteome and total proteome in healthy young and old human skeletal muscle following acute resistance exercise (ResEX) and essential amino acid (EAA) ingestion. Ageing led to global suppression of the growth-induced global phosphoproteome, despite intact mTORC1 activation in old muscle. Our results identify widespread effects of ageing on skeletal muscle growth and highlight novel pathways for therapeutic development in aged skeletal muscle.
Open AccessAgeing blunts the phospho-proteomic response to resistance exercise in humans
Ageing blunts the adaptive growth response in human skeletal muscle. To define the molecular processes underlying this impairment, we performed unbiased analysis of the phosphoproteome and total proteome in healthy young and old human skeletal muscle following acute resistance exercise (ResEX) and essential amino acid (EAA) ingestion. Ageing led to global suppression of the growth-induced global phosphoproteome, despite intact mTORC1 activation in old muscle. Our results identify widespread effects of ageing on skeletal muscle growth and highlight novel pathways for therapeutic development in aged skeletal muscle.